FIELD: chemistry.
SUBSTANCE: disclosed are antibodies which selectively neutralise bioactivity of at least two subtypes of interferon-alpha (IFNα) protein towards A, 2, B2, C, F, G, H2, I, JI, K, 4a, 4b and WA protein subtypes, and neutralise at least one bioactivity of IFNα protein subtype D. The invention also discloses application of the antibodies to prepare a medicinal agent. The invention also discloses a host cell producing the antibody and a hybridome. The disclosed antibodies are effective in detecting IFNα subtypes in a sample or tissue and/or for therapeutic application which involves treatment and/or amelioration in case of a disease associated with IFNα, such as SLE, lupus, type I diabetes, psoriasis, AIDS and graft-versus-host disease.
EFFECT: highly effective treatment.
37 cl, 17 dwg, 10 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
| ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
| ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION | 2005 |
|
RU2412202C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
| MONOCLONAL ANTIBODY CAPABLE OF NEUTRALIZING BIOLOGICAL ACTIVITY OF HUMAN INTERFERON BETA 1A | 2018 |
|
RU2729391C2 |
| MONOCLONAL ANTIBODY TO HUMAN INTERFERON BETA-1A | 2018 |
|
RU2728696C2 |
| VARIABLE DOMAINS OF LIGHT AND HEAVY CHAIN OF THE MOUSE MONOCLONAL ANTIBODY AGAINST INTERFERON ALPHA (IFN-α) HUMAN ANTIGEN BINDING FRAGMENTS (FAb) AGAINST HUMAN IFN-α COMPRISING SAID DOMAINS | 2018 |
|
RU2694672C1 |
| RECOMBINANT Fab-scFv BASED ON A NEUTRALISING ANTIBODY AGAINST HUMAN BETA-1A INTERFERON AND AN ANTIBODY AGAINST HUMAN ErbB2 RECEPTOR | 2019 |
|
RU2748953C1 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
